Andrew Tsai
Stock Analyst at Jefferies
(0)
# 5084
Out of 5,370 analysts
25
Total ratings
20.00%
Success rate
-32.04%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SRPT Sarepta Therapeutics | Maintains: Buy | 125 54 | 20.99 | 157.27% | 2 | Jun 16, 2025 | |
VRNA Verona Pharma | Maintains: Strong Buy | 95 110 | 92.58 | 18.82% | 1 | Jun 11, 2025 | |
RCKT Rocket Pharmaceutica... | Downgrades: Hold | 29 3 | 2.88 | -13.19% | 2 | May 28, 2025 | |
AXSM Axsome Therapeutics | Initiates Coverage On: Buy | 200 | 101.88 | 96.31% | 1 | Apr 7, 2025 | |
BEKE KE Holdings | Maintains: Overweight | 19 27 | 19.2 | 40.62% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 5 1 | n/a | n/a | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 4 13 | 0.73 | 1680.82% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | 11.15 | 213.9% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 33 | 2.31 | 1328.57% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 1 15 | 2.34 | 541.03% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 3 | 0.66 | 354.55% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 32 3 | n/a | n/a | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | 7.87 | 154.13% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 55 70 | n/a | n/a | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 27 | 2.23 | 1110.76% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 18 | n/a | n/a | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 16 23 | 32.07 | -28.28% | 1 | Jun 1, 2020 |